Exhibit Booths are open Saturday 8:45am - 9:00am and 12:05pm - 1:05pm.
Having technical issues with zoom? Call into the booth and use the meeting ID: 8104 159 8624
+1 669 900 9128 US (San Jose)
+1 346 248 7799 US (Houston)
+1 253 215 8782 US (Tacoma)
+1 312 626 6799 US (Chicago)
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington DC)
Find your local number: https://us02web.zoom.us/u/kcgMX6H3vN
Hemophilia, a rare hematological disease, has been a key focus for Pfizer, and significant progress has been made. A century ago, children with hemophilia, a blood-clotting disorder that causes abnormal bleeding, rarely survived past the age of eight. Today, it is a treatable rare disease, and patients who receive treatment can expect to live relatively normal and active lives. At Pfizer, developing therapies for this disease has been a priority for over 18 years. While there is still no cure, we are moving closer to one with pioneering approaches.
La hemofilia, una enfermedad hematológica poco común, ha sido un enfoque clave para Pfizer y se han logrado avances significativos. Hace un siglo, los niños con hemofilia, un trastorno de la coagulación de la sangre que causa sangrado anormal, rara vez sobrevivían después de los ocho años. Hoy en día, es una enfermedad rara tratable, y los pacientes que reciben tratamiento pueden esperar llevar una vida relativamente normal y activa. En Pfizer, el desarrollo de terapias para esta enfermedad ha sido una prioridad durante más de 18 años. Si bien todavía no hay cura, nos estamos acercando a uno con enfoques pioneros.
https://www.pfizer.com/health-wellness/disease-conditions/rare-diseases/hemophilia
